Maitane M. E.
- Country
- Spain
- Department
- Oncology
Research Overview
- Phase III Randomized Trial of Trastuzumab, Alpelisib, and Fulvestrant Versus Trastuzumab and Chemotherapy in PIK3CA-Mutated HER2+ Advanced Breast Cancer
- Phase III Evaluation of Sacituzumab Govitecan Versus Physician's Choice in HER2-Negative Breast Cancer with High Relapse Risk Post-Neoadjuvant Therapy
Data & Insights
Has run more than one trial at 6 of 151 partner sites.
Specializations
Breast Cancer Specialization
The investigator demonstrates significant expertise in treating advanced breast cancer, with particular focus on specific molecular subtypes including HER2-positive and HER2-negative variants.
- Advanced and Metastatic Disease Management
- Molecular Subtype-Specific Approaches
- High-Risk Patient Treatment
Shows specific interest in PIK3CA-mutated breast cancers and their therapeutic management.
Targeted Therapy Expertise
Focuses on innovative therapeutic approaches utilizing targeted biological agents including trastuzumab-based treatments and novel compounds like sacituzumab govitecan.
- Antibody-Drug Conjugates
- Combination Therapy Strategies
- Personalized Treatment Approaches
Specializes in developing treatment strategies for patients who have received prior therapeutic interventions.
Precision Medicine Applications
Expertise in molecular profiling-based treatment selection and implementation of biomarker-driven therapy approaches in breast cancer care.
- Molecular Testing Integration
- Treatment Response Assessment
- Risk Stratification Strategies
Particularly interested in addressing therapeutic needs of patients with specific genetic alterations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.